Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,870 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sexually Transmitted Diseases, Viral Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With Proton Pump Inhibitor

NCT00357240
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Atazanavir/Ritonavir, Atazanavir/Ritonavir+Omeprazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2011 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Not applicable Interventional

Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis

NCT00002010
View directory record Official record
Conditions
Meningitis, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Tucson, Arizona • San Diego, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

NCT00801697
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Vaccine, DNA Vaccine placebo, rAd35, rAd35 placebo, rAd5, rAd5 placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Results available

Expanded Access Program for Maraviroc At Multiple Centers

NCT00426660
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
1,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
190
States / cities
Birmingham, Alabama • Hobson City, Alabama • Tucson, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure

NCT00000691
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm

NCT00076817
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
ALVAC-HIV (vCP205)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 3 Interventional

Cognitive Behavioral Therapy Combined With Antidepressants to Reduce HIV Risk and Drug Relapse Among Depressed Intravenous Drug Users

NCT00183768
View directory record Official record
Conditions
HIV Infections, Depression, Substance-Related Disorders
Interventions
Cognitive Behavioral Therapy, Psychopharmacology
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention

NCT01752504
View directory record Official record
Conditions
HIV Infection
Interventions
Community Mobilization
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years and older
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 15, 2026, 6:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

NCT04303117
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
PDS01ADC, M7824
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Not applicable Interventional Results available

Lifestyle Modification and Metformin Use in the Treatment of HIV

NCT00399360
View directory record Official record
Conditions
HIV Infections, Metabolic Syndrome X
Interventions
Metformin, Placebo, Lifestyle Modification
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 15, 2026, 6:28 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289482
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 1 Interventional

Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.

NCT00000818
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 3 Interventional

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

NCT00002410
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Dupont Merck
Industry
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

NCT00001020
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1IIIB, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 1 Interventional

A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.

NCT00000704
View directory record Official record
Conditions
HIV Infections
Interventions
Zalcitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

NCT03393468
View directory record Official record
Conditions
HIV Infections
Interventions
Dapivirine gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 15, 2026, 6:28 AM EDT
Approved For Marketing No phase listed Expanded access

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

NCT00062660
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
35
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 1 Interventional

Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia

NCT00002120
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Trimethoprim, Sulfamethoxazole, Dapsone, Leucovorin calcium
Drug
Lead sponsor
U.S. Bioscience
Industry
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 3 Interventional

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00002105
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal), Bleomycin sulfate, Vincristine sulfate
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

NCT00896051
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
Atazanavir (ATV) 300 mg, Atazanavir (ATV) 400 mg, Ritonavir (rtv) 100 mg, Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs), Etravirine (ETR) 200 mg, Tenofovir disoproxil fumarate (TDF) 300 mg
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
10
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia

NCT04411849
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Best Practice, HPV Self-Collection, Informational Intervention, Patient Navigation Program
Other · Procedure · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years to 64 Years · Female only
Enrollment
802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Lexington, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 15, 2026, 6:28 AM EDT
Terminated Phase 2 Interventional

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts

NCT03158974
View directory record Official record
Conditions
Condylomata Acuminata
Interventions
East Indian Sandalwood Oil Cream
Drug
Lead sponsor
ViroXis Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Not applicable Interventional

Emotional Disclosure in HIV

NCT00067704
View directory record Official record
Conditions
HIV Infections
Interventions
Trauma writing, Writing about daily events
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 15, 2026, 6:28 AM EDT
Completed Phase 3 Interventional

Enhancing Communication and HIV Outcomes

NCT00675610
View directory record Official record
Conditions
HIV Infections
Interventions
communication training
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 15, 2026, 6:28 AM EDT